If you prescribe compounded peptides, the difference between a 503A pharmacy and a 503B outsourcing facility is not a procurement detail. It determines what may lawfully be made for your patient, who may hold it, and whose name is on the problem if a regulator asks.
Most clinicians learn this the hard way, usually after a supplier tells them something that is not quite true.
The two categories, briefly
Both categories were created by the Drug Quality and Security Act of 2013, passed after the 2012 New England Compounding Center meningitis outbreak.
A 503A compounding pharmacy compounds for an identified patient against a valid prescription. It is regulated primarily by the state board of pharmacy. It is exempt from certain FDA requirements — including new drug approval and cGMP manufacturing standards — precisely because it is filling individual prescriptions rather than manufacturing.
A 503B outsourcing facility may compound in bulk, without patient-specific prescriptions, and may sell to clinics for office stock. In exchange it registers with the FDA, must comply with cGMP, and is subject to FDA inspection.
The practical translation: if you want product on your shelf without a patient name attached to it, that is 503B territory. If it is made for one named patient, that is 503A.
The bulks list is where peptides actually live or die
Here is the part that catches clinicians out. A 503A pharmacy cannot compound from just any substance. The active ingredient must fall into one of three buckets: it is a component of an FDA-approved drug, it appears on the FDA’s 503A bulk drug substances list, or it has an applicable USP or NF monograph.
Most of the peptides discussed in wellness and regenerative practice are none of those things. They are not approved drugs, and they are not on the bulks list. That is the whole reason the compounded-peptide supply has been so unstable since 2023 — not because pharmacies changed their minds, but because the substances themselves were never securely eligible.
The FDA sorts nominated substances into review categories. Category 2 designates substances identified as presenting significant safety risks, which effectively bars compounding. In 2023 a number of widely used peptides moved into Category 2, and protocols built on them collapsed.
What changed in 2026 — and what did not
Two developments matter, and they are routinely misrepresented by suppliers.
April 2026: the FDA removed twelve peptides from Category 2, including BPC-157, TB-500, KPV, epithalon, MOTS-c, Semax, DSIP, LL-37, DiHexa, PEG-MGF, Melanotan II and injectable GHK-Cu. Removal from Category 2 is not approval. It withdraws the safety-risk designation and returns the substance to pending evaluation. It does not place anything on the bulks list.
July 23–24, 2026: the FDA’s Pharmacy Compounding Advisory Committee reviewed seven nominated peptides and voted to recommend six for the 503A bulks list — BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. It voted against Emideltide, the nomination name for DSIP. The committee did so over its own FDA staff briefing, which had recommended adding none of them.
Ready to put this into practice?
Explore Empire's hands-on, CME-accredited Functional & Regenerative Medicine courses — live patients, expert faculty, and ongoing mentorship.
A PCAC recommendation is advisory. A substance is added to the 503A list only when the FDA completes notice-and-comment rulemaking, which it has not done, and for which no timetable has been published. Until then, none of those six is eligible for legitimate 503A compounding.
If a pharmacy tells you a peptide is “now approved” or “cleared for compounding” on the strength of either event, that is your signal to ask harder questions.
Questions worth asking a compounding partner
- Which are you — 503A or 503B? Some organisations operate both under one brand. Ask which entity is filling your order.
- On what basis is this substance eligible? Component of an approved drug, bulks list, or monograph. If the answer is none of the three, there is no lawful pathway.
- Who tested this lot, and may I see the Certificate of Analysis? A COA produced by the seller, or one not tied to your specific lot, tells you nothing.
- What is your inspection history? A 503B is FDA-inspected and those records exist. A 503A answers to its state board.
- Are you shipping office stock without prescriptions? If a 503A is doing that, the compliance problem is not only theirs.
Where the liability actually sits
Prescribers sometimes assume that using a licensed pharmacy transfers the risk. It does not. You remain responsible for the clinical decision, for informed consent covering non-FDA-approved use, and for documenting the medical necessity behind the prescription. A pharmacy’s licence does not make an ineligible substance eligible, and it does not convert an unapproved compound into a standard of care.
The defensible posture is unglamorous: know which entity you are buying from, know why the substance is eligible, document why this patient needs it, and re-verify status rather than assume it holds.
Frequently asked questions
What is the difference between 503A and 503B?
A 503A pharmacy compounds for an identified patient against a valid prescription and answers primarily to the state board. A 503B outsourcing facility compounds in bulk without patient-specific prescriptions, registers with the FDA, and must meet cGMP.
Can a 503A pharmacy compound peptides?
Only where the substance is eligible — a component of an approved drug, on the 503A bulks list, or covered by a USP or NF monograph. Most wellness peptides are none of these.
Did the FDA approve peptides for compounding in 2026?
No. Twelve were removed from Category 2 in April, and six were recommended for the bulks list by the advisory committee in July. Neither step is approval, and rulemaking has not been completed.
Can I buy peptides for office use?
Office stock without patient-specific prescriptions is a 503B function, and only for substances a 503B may lawfully compound. A 503A supplying office stock is a warning sign.
Does using a licensed pharmacy protect me?
Not by itself. The prescriber remains responsible for the clinical decision, consent, and documentation of medical necessity.
What training do I need to prescribe compounded peptides?
No specific credential is legally required — you prescribe within your existing scope of practice. What the situation actually demands is knowing whether the substance is eligible for compounding at all, being able to document medical necessity, and obtaining consent that accurately describes non-FDA-approved use. Certification demonstrates that competence; it does not expand your scope or make an ineligible substance eligible.
Learn the framework properly
Module 2 of the Empire Peptide Therapy Certification covers the 503A and 503B framework, the bulks list, pharmacy vetting and Certificates of Analysis; Module 12 covers the healthcare-law layer, taught with a healthcare law firm. Pharmacists and compounding professionals can see the pharmacy-specific track here.
Related: the Peptide Formulary lists all 128 agents taught in the program with each one’s current regulatory status.
